- Home
- MVST vs XERS Comparison
MVST vs XERS Comparison
Compare MVST & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVST | XERS |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.8M | 1.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MVST | XERS |
|---|---|---|
| Price | $1.51 | $6.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $6.00 | ★ $10.83 |
| AVG Volume (30 Days) | ★ 4.2M | 1.6M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $24.55 | $34.37 |
| Revenue Next Year | $17.08 | $22.86 |
| P/E Ratio | ★ N/A | $643.50 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $1.26 | $4.30 |
| 52 Week High | $7.12 | $10.08 |
Technical Indicators
Market Signals| Indicator | MVST | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 54.88 |
| Support Level | N/A | $6.26 |
| Resistance Level | $2.49 | $6.41 |
| Average True Range (ATR) | 0.14 | 0.29 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 25.92 | 38.65 |
Price Performance
Historical ComparisonAbout MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.